免疫治疗在肝细胞癌治疗中的进展
投稿时间:2017-01-18  最后修改时间:2017-05-31  点此下载全文
引用本文:郭玲玲,仇金荣.免疫治疗在肝细胞癌治疗中的进展[J].药学实践杂志,2017,35(4):362~366
摘要点击次数: 67
全文下载次数: 92
作者单位E-mail
郭玲玲 第二军医大学附属东方肝胆外科医院肿瘤生物治疗科, 上海 200438  
仇金荣 第二军医大学附属东方肝胆外科医院肿瘤生物治疗科, 上海 200438 jrqiu@njmu.edu.cn 
中文摘要:肝细胞癌(HCC)是全球发病率和致死率都很高的恶性肿瘤。目前以手术治疗为主的治疗方法远难以达到理想的效果。肿瘤免疫治疗,包括树突状细胞诱导的杀伤细胞(DC-CIK)、肿瘤浸润淋巴细胞(TIL)、嵌合抗原受体T细胞(CAR-T)、免疫检查点阻滞剂(如PD-1阻滞剂、CTL4阻滞剂)等,是近年发展迅速且具有良好前景的肿瘤治疗新方法。本综述着重介绍PD-1阻滞剂、DC-CIK细胞、TIL细胞在治疗肝细胞癌中取得的进展,并对本课题组发明的多能免疫杀伤转基因细胞(PIK)做简要介绍。
中文关键词:肝细胞癌  肿瘤免疫治疗  树突状细胞  PD-1阻滞剂  多能免疫杀伤转基因细胞
 
Progress in immunotherapy for hepatocellular carcinoma
Abstract:Hepatocellular carcinoma is a malignant tumor with high morbidity and mortality globally. The therapeutic results on hepatocellular carcinoma with surgery and other classical treatments are not satisfactory. Tumor immunotherapies, such as dendritic cells and cytokine-induced killer cells (DC-CIK), tumor-infiltrating lymphocytes (TIL), chimeric antigen receptor T cells (CAR-T), immune checkpoint blockade (such as PD-1 blockade,CTL4 blockade) etc., are very promising new therapeutic approaches. In this paper, the progresses in the immunotherapy, mainly on PD-1, DC-CIK, TIL, are reviewed. Also pluripotent immune killer cells (PIK) which was developed in our lab was briefly introduced.
keywords:hepatocellular carcinoma  tumor immunotherapy  DC  PD-1 blockade  PIK
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮